Upregulated expression of SNHG12 showed significant association with unfavorable survival and indicated worse clinicopathological outcomes in multiple kinds of human cancer, and therefore might serve as a promising prognosis biomarker and therapeutic target for cancers. This evidence concerns the gene SNHG12 and cancer.